Use of lecanemab for the treatment of Alzheimer's disease: A systematic review
Abstract Purpose The US Food and Drug Administration authorized lecanemab for the therapeutic use of Alzheimer's disease (AD) in January 2023. To assess the effectiveness and safety of lecanemab in treating AD, we thoroughly examined the studies that are currently accessible. Method Preferred Report...
Wedi'i Gadw mewn:
| Prif Awduron: | , , |
|---|---|
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Wiley
2024-06-01
|
| Cyfres: | Brain and Behavior |
| Pynciau: | |
| Mynediad Ar-lein: | https://doi.org/10.1002/brb3.3592 |
| Tagiau: |
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|